Rosetta Genomics last week reported a drop in its first-quarter loss as it trimmed business costs and research and development spending.

For the three-month period ended March 30, the company's net loss fell to $1.7 million, or $0.07 per share, from a year-ago loss of $3.7 million, or $0.23 per share.

R&D expenses in the quarter shrank to $1 million from $1.6 million in the same period a year earlier, while marketing and business costs dropped to $625,000 from $1.2 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.